Table 3.

Relationships between serum iron, ferritin, and hepcidin and categorical variables.

	Female		Male
Iron, mg/dL	203	72.1 ± 33.2	59	76.0 ± 38.8	0.643
Ferritin, ng/mL	203	59.4 ± 60.9	59	73.2 ± 71.6	0.073
Hepcidin, ng/mL	203	13.9 ± 18.9	59	15.4 ± 22.3	0.905
	Anti-resorption treatment (−)		Anti-resorption treatment (+)
Iron, mg/dL	97	71.8 ± 34.6	165	73.7 ± 34.5	0.650
Ferritin, ng/mL	97	70.6 ± 73.5	165	57.7 ± 56.7	0.142
Hepcidin, ng/mL	97	16.1 ± 21.5	165	13.2 ± 18.6	0.193
	Vitamin D treatment (−)		Vitamin D treatment (+)
Iron, mg/dL	225	72.8 ± 34.4	37	74.1 ± 35.5	0.961
Ferritin, ng/mL	225	60.0 ± 62.6	37	77.8 ± 68.4	0.050
Hepcidin, ng/mL	225	13.8 ± 19.4	37	17.2 ± 21.4	0.334
	PSL (−)		PSL (+)
Iron, mg/dL	67	83.1 ± 31.4	195	69.5 ± 34.9	0.001
Ferritin, ng/mL	67	63.6 ± 54.6	195	62.1 ± 66.5	0.222
Hepcidin, ng/mL	67	13.0 ± 12.3	195	14.7 ± 21.7	0.083
	MTX (−)		MTX (+)
Iron, mg/dL	124	72.8 ± 35.4	138	73.2 ± 33.8	0.930
Ferritin, ng/mL	124	55.8 ± 52.9	138	68.5 ± 71.5	0.332
Hepcidin, ng/mL	124	13.5 ± 19.0	138	15.0 ± 20.4	0.938
	bDMARDs (−)		bDMARDs (+)
Iron, mg/dL	174	69.8 ± 32.8	88	79.4 ± 36.9	0.046
Ferritin, ng/mL	174	68.7 ± 69.2	88	50.1 ± 48.9	0.023
Hepcidin, ng/mL	174	15.8 ± 20.2	88	11.3 ± 18.4	0.008
	Tocilizumab (−)		Tocilizumab (+)
Iron, mg/dL	241	71.2 ± 33.8	21	93.4 ± 36.9	0.007
Ferritin, ng/mL	241	64.4 ± 65.6	21	40.4 ± 24.2	0.330
Hepcidin, ng/mL	241	14.9 ± 20.2	21	7.5 ± 10.0	0.174
	Iron agent (−)		Iron agent (+)
Iron, mg/dL	253	72.7 ± 34.8	9	81.6 ± 25.3	0.238
Ferritin, ng/mL	253	61.2 ± 62.6	9	99.7 ± 83.5	0.142
Hepcidin, ng/mL	253	14.1 ± 19.9	9	19.8 ± 14.0	0.055

Data are numbers of patients, mean ± S.D.

Anti-resorption treatment included bisphosphonate and denosumab use. bDMARDs included anti-TNF and tocilizumab treatment. Vitamin D treatment was the use of active form of vitamin D preparation.

PSL, prednisolone; MTX, methotrexate; DMARDs, disease-modifying antirheumatic drugs.